Teva Pharmaceutical Industries (NYSE:TEVA) Rating Lowered to Hold at Jefferies Financial Group

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) was downgraded by equities researchers at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. They presently have a $12.00 price objective on the stock, up from their previous price objective of $10.00. Jefferies Financial Group’s price objective indicates a potential upside of 15.27% from the company’s previous close.

A number of other research analysts have also recently issued reports on TEVA. JPMorgan Chase & Co. cut shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and lowered their price target for the company from $11.00 to $10.00 in a research report on Monday, November 14th. BMO Capital Markets lowered their price target on shares of Teva Pharmaceutical Industries from $11.00 to $10.00 and set a “market perform” rating for the company in a research report on Monday, November 7th. Piper Sandler lowered their price target on shares of Teva Pharmaceutical Industries from $8.00 to $7.00 and set an “underweight” rating for the company in a research report on Wednesday, November 23rd. StockNews.com began coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 12th. They set a “buy” rating for the company. Finally, UBS Group cut shares of Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating in a research report on Friday, November 4th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.67.

Teva Pharmaceutical Industries Trading Down 1.3 %

Shares of TEVA opened at $10.41 on Thursday. The firm’s 50-day moving average price is $9.38 and its 200-day moving average price is $8.98. The firm has a market capitalization of $11.56 billion, a price-to-earnings ratio of -8.97 and a beta of 1.19. The company has a current ratio of 0.99, a quick ratio of 0.66 and a debt-to-equity ratio of 1.94. Teva Pharmaceutical Industries has a 1-year low of $6.78 and a 1-year high of $11.44.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last announced its earnings results on Thursday, November 3rd. The company reported $0.56 earnings per share for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). The company had revenue of $3.60 billion for the quarter, compared to the consensus estimate of $3.86 billion. Teva Pharmaceutical Industries had a negative net margin of 8.52% and a positive return on equity of 26.97%. Sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.4 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 3.7% during the first quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock valued at $391,081,000 after purchasing an additional 1,494,814 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 9.5% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 21,380,200 shares of the company’s stock valued at $172,533,000 after purchasing an additional 1,847,280 shares during the last quarter. Phoenix Holdings Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 11.8% during the third quarter. Phoenix Holdings Ltd. now owns 20,831,080 shares of the company’s stock valued at $162,941,000 after purchasing an additional 2,201,291 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Teva Pharmaceutical Industries by 8.1% during the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 18,962,766 shares of the company’s stock valued at $138,282,000 after purchasing an additional 1,424,200 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Teva Pharmaceutical Industries by 7.6% during the third quarter. State Street Corp now owns 14,901,933 shares of the company’s stock valued at $120,259,000 after purchasing an additional 1,055,920 shares during the last quarter. 50.39% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

(Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Featured Stories

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.